Reconstituting the Reverse
Cholesterol Transport Pathway
LipimetiX
LipimetiX is a privately held biopharmaceutical company developing novel ligand replacement therapy to treat severely high cholesterol and triglyceride levels in patients that are not responsive to currently available therapies, and to treat acute coronary syndrome by rapidly decreasing arterial cholesterol content and inflammation.
LipimetiX' technology is based upon small amphipathic helical peptide mimetics of Apolipoprotein E, a critical protein that directs lipid rich lipoproteins to receptors on the liver.
The Company's lead product, AEM-18, is being developed for genetically induced refractory hypercholesterolemia, an orphan indication that leads to early cardiovascular disease.
LipimetiX' technology is based upon small amphipathic helical peptide mimetics of Apolipoprotein E, a critical protein that directs lipid rich lipoproteins to receptors on the liver.
The Company's lead product, AEM-18, is being developed for genetically induced refractory hypercholesterolemia, an orphan indication that leads to early cardiovascular disease.
The Company's second product, AEM-28, is being developed for acute coronary syndrome